|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| «12...56789101112131415...1819» |
- || Enbrel (etanercept) / Pfizer, Amgen
Trial completion date: Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept (clinicaltrials.gov) - May 20, 2014
P4, N=217, Completed, Sponsor: Amgen
Trial completion date: Oct 2014 --> May 2014
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept (clinicaltrials.gov) - May 20, 2014
P4, N=217, Completed, Sponsor: Amgen
Trial completion date: Oct 2014 --> May 2014 Active, not recruiting --> Completed
- |||| neihulizumab (ALTB-168) / AltruBio
Trial completion: Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients (clinicaltrials.gov) - May 20, 2014
P2a, N=54, Completed, Sponsor: AbGenomics B.V Taiwan Branch
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment closed: A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis (clinicaltrials.gov) - May 19, 2014
P3, N=50, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial primary completion date, IO biomarker: Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques (clinicaltrials.gov) - May 18, 2014
P2, N=10, Not yet recruiting, Sponsor: Tissa Hata, MD
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2014 --> Aug 2015
- Trial initiation date, IO biomarker: Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques (clinicaltrials.gov) - May 18, 2014
P2, N=10, Not yet recruiting, Sponsor: Tissa Hata, MD
Trial primary completion date: Oct 2014 --> Aug 2015 Initiation date: Jan 2014 --> Aug 2014
- Trial completion date, IO biomarker: Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques (clinicaltrials.gov) - May 18, 2014
P2, N=10, Not yet recruiting, Sponsor: Tissa Hata, MD
Initiation date: Jan 2014 --> Aug 2014 Trial completion date: Oct 2014 --> Sep 2015
- || Sorilux (calcipotriene foam) / Mayne Pharma
Trial primary completion date, Combination therapy: Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis (clinicaltrials.gov) - May 15, 2014
P4, N=60, Active, not recruiting, Sponsor: Leon Kircik, M.D.
Trial completion date: Oct 2014 --> Sep 2015 Trial primary completion date: Jan 2014 --> May 2014
- | Bimzelx (bimekizumab) / UCB
Clinical: Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis (clinicaltrials.gov) - May 15, 2014
P1, N=50, Recruiting, Sponsor: UCB Celltech
- ||| Sorilux (calcipotriene foam) / Mayne Pharma
Enrollment closed, Combination therapy: Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis (clinicaltrials.gov) - May 15, 2014
P4, N=60, Active, not recruiting, Sponsor: Leon Kircik, M.D.
Trial primary completion date: Jan 2014 --> May 2014 Recruiting --> Active, not recruiting
- |||| Trial primary completion date: A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305) (clinicaltrials.gov) - May 12, 2014
P3, N=222, Completed, Sponsor: Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2014 --> Mar 2014
- ||| Trial completion date: A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305) (clinicaltrials.gov) - May 12, 2014
P3, N=222, Completed, Sponsor: Therapeutics, Inc.
Trial primary completion date: Feb 2014 --> Mar 2014 Trial completion date: Feb 2014 --> Mar 2014
- ||||||| Trial completion: A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305) (clinicaltrials.gov) - May 12, 2014
P3, N=222, Completed, Sponsor: Therapeutics, Inc.
Trial completion date: Feb 2014 --> Mar 2014 Recruiting --> Completed
- | Tremfya (guselkumab) / J&J
Enrollment change: A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis (clinicaltrials.gov) - May 11, 2014
P2, N=49, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Completed N=63 --> 49
- | Tremfya (guselkumab) / J&J
Enrollment closed: A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis (clinicaltrials.gov) - May 11, 2014
P2, N=49, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
N=63 --> 49 Recruiting --> Active, not recruiting
- Humira (adalimumab) / Eisai, AbbVie
Trial termination: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 10, 2014
P2, N=8, Terminated, Sponsor: Wayne State University
Recruiting --> Active, not recruiting Recruiting --> Terminated; side effect and poor clinical outcome
- Humira (adalimumab) / Eisai, AbbVie
Trial completion date: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 10, 2014
P2, N=8, Terminated, Sponsor: Wayne State University
Recruiting --> Terminated; side effect and poor clinical outcome Trial completion date: Jun 2013 --> May 2014
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 10, 2014
P2, N=8, Terminated, Sponsor: Wayne State University
Trial completion date: Jun 2013 --> May 2014 N=10 --> 8
- Trial completion date: Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis (clinicaltrials.gov) - May 7, 2014
P3, N=30, Completed, Sponsor: Medical University of Vienna
N=10 --> 8 Trial completion date: Dec 2013 --> Apr 2014
- pimecrolimus topical / Generic mfg., clobetasol propionate topical / Generic mfg.
Trial completion date: Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus (clinicaltrials.gov) - May 7, 2014
P2, N=38, Completed, Sponsor: Center for Vulvovaginal Disorders
Trial completion date: Dec 2013 --> Apr 2014 Trial completion date: Oct 2006 --> Oct 2009
- Trial completion: Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis (clinicaltrials.gov) - May 7, 2014
P3, N=30, Completed, Sponsor: Medical University of Vienna
Trial completion date: Oct 2006 --> Oct 2009 Active, not recruiting --> Completed
- | pimecrolimus topical / Generic mfg., clobetasol propionate topical / Generic mfg.
Trial completion: Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus (clinicaltrials.gov) - May 7, 2014
P2, N=38, Completed, Sponsor: Center for Vulvovaginal Disorders
Active, not recruiting --> Completed Recruiting --> Completed
- | Impoyz (clobetasol) / Encore
New P2 trial: DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 4, 2014
P2, N=50, Recruiting, Sponsor: Promius Pharma, LLC
- ||||| namilumab (IZN-101) / Amgen, Izana Biosci
Clinical: Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis (clinicaltrials.gov) - Apr 30, 2014
P2, N=100, Not yet recruiting, Sponsor: Takeda
- | Toctino (alitretinoin) / Basilea
Trial completion: Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis (clinicaltrials.gov) - Apr 30, 2014
P2, N=33, Completed, Sponsor: Stiefel, a GSK Company
Recruiting --> Completed Active, not recruiting --> Completed
- || Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Apr 29, 2014
P4, N=100, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Nov 2016
- || Enbrel (etanercept) / Pfizer, Amgen
Trial completion date: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Apr 29, 2014
P4, N=100, Recruiting, Sponsor: Amgen
Trial primary completion date: Jul 2015 --> Nov 2016 Trial completion date: Sep 2015 --> Jan 2017
- ||||| Erelzi (etanercept-szzs) / Sandoz
Enrollment closed: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel (clinicaltrials.gov) - Apr 23, 2014
P3, N=546, Active, not recruiting, Sponsor: Sandoz
Trial completion date: Sep 2015 --> Jan 2017 Recruiting --> Active, not recruiting
- ||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Apr 17, 2014
P3, N=400, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Initiation date: Jan 2014 --> Jan 2014
- ||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Enrollment closed: Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Apr 15, 2014
P3, N=350, Active, not recruiting, Sponsor: Amgen
Initiation date: Jan 2014 --> Jan 2014 Recruiting --> Active, not recruiting
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment closed: GESTURE: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (clinicaltrials.gov) - Apr 13, 2014
P3, N=201, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment closed: TRANSFIGURE: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (clinicaltrials.gov) - Apr 13, 2014
P3, N=195, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment (clinicaltrials.gov) - Apr 10, 2014
P=N/A, N=52, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=177 --> 52
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment (clinicaltrials.gov) - Apr 10, 2014
P=N/A, N=52, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=177 --> 52 Active, not recruiting --> Completed
- bexarotene/betamethasone dipropionate (LAS 41004) / Almirall
New P1/2 trial: Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test (clinicaltrials.gov) - Apr 9, 2014
P1/2, N=18, Recruiting, Sponsor: Almirall, S.A.
- || Humira (adalimumab) / AbbVie
Enrollment change: Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=555, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed N=800 --> 555
- |||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Enrollment open: AMVISION-1: Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis (clinicaltrials.gov) - Apr 7, 2014
P3, N=630, Recruiting, Sponsor: Amgen
N=800 --> 555 Not yet recruiting --> Recruiting
- New P4 trial: Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis (clinicaltrials.gov) - Apr 6, 2014
P4, N=21, Recruiting, Sponsor: Tufts Medical Center
- prednisone / Generic mfg.
New P2 trial, HEOR: The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus (clinicaltrials.gov) - Apr 6, 2014
P2, N=30, Enrolling by invitation, Sponsor: October 6 University
- Enrollment open: Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis (clinicaltrials.gov) - Apr 3, 2014
P4, N=21, Recruiting, Sponsor: Tufts Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- prednisone / Generic mfg.
Enrollment open, HEOR: The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus (clinicaltrials.gov) - Apr 2, 2014
P2, N=30, Enrolling by invitation, Sponsor: October 6 University
Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
- Enbrel (etanercept) / Pfizer, Amgen
Trial termination: Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis (clinicaltrials.gov) - Apr 1, 2014
P=N/A, N=40, Terminated, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Enrolling by invitation Recruiting --> Terminated; Difficulty in recruitment.
- | Prurisol (abacavir gylcolate) / Innovation Pharma
New P1 trial: Bioequivalence and Pharmacokinetic Study of Prurisol (clinicaltrials.gov) - Mar 31, 2014
P1, N=18, Recruiting, Sponsor: Cellceutix Corporation
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Immunomodulating: Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. (clinicaltrials.gov) - Mar 26, 2014
P=N/A, N=52, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Terminated; Difficulty in recruitment. Recruiting --> Active, not recruiting
- Metoject (methotrexate autopen) / Medac
New P1 trial: Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen (clinicaltrials.gov) - Mar 24, 2014
P1, N=35, Completed, Sponsor: medac GmbH
- Metoject (methotrexate autopen) / Medac
Trial completion: Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen (clinicaltrials.gov) - Mar 24, 2014
P1, N=35, Completed, Sponsor: medac GmbH
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- | Trial suspension, Patient reported outcomes: Post Marketing Observational Study on Venezuelan Patients With Psoriasis (clinicaltrials.gov) - Mar 19, 2014
P=N/A, N=100, Suspended, Sponsor: Abbott (Venezuela)
Not yet recruiting --> Completed Enrolling by invitation --> Suspended
- New P2 trial: Mechanistic Study of Indigo Naturalis in Treating Psoriasis (clinicaltrials.gov) - Mar 12, 2014
P2, N=20, Completed, Sponsor: Chang Gung Memorial Hospital
- ||| bleselumab (ASKP1240) / Astellas, Kyowa Kirin
Enrollment closed: A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Mar 12, 2014
P2, N=60, Active, not recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Enrolling by invitation --> Suspended Recruiting --> Active, not recruiting
- vancomycin / Generic mfg., doxycycline / Generic mfg.
Trial completion: Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Mar 10, 2014
P=N/A, N=178, Completed, Sponsor: New York University School of Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Completed